Although anthracycline antibiotics are among the most useful chemotherapy agents, the risk of producing cardiomyopathy and the absence of a reliable noninvasive technique to predict subclinical cardiomyopathy remain a major problem. We retrospectively reviewed our experience with anthracyclines over a 5-year period. Cardiomyopathy developed in 6 of 112 patients (5.3%) treated with anthracyclines and was fatal in 5 of the 6 patients. Our incidence and mortality rates are higher than those previously reported.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/mpo.2950120113 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Factors Associated With the Recovery of Left Ventricular Ejection Fraction in Patients With Anthracycline-Induced Left Ventricular Dysfunction.
J Cardiovasc Pharmacol Ther
January 2025
Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
Background: Neurohormonal blocking drugs, like beta-blockers, angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin receptor blockers (ARBs), are recommended for treating anthracycline-induced left ventricular dysfunction (AILVD). However, there is limited evidence supporting their benefit. Therefore, this study evaluated associations of neurohormonal blockers and other clinical factors with recovery of left ventricular ejection fraction (LVEF) in patients with AILVD.
View Article and Find Full Text PDFInflammation in Chemotherapy-Induced Cardiotoxicity.
Curr Cardiol Rep
December 2024
Division of Cardiology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Purpose Of Review: In this review we describe the role of inflammation in chemotherapy-induced cardiotoxicity with a particular focus on anthracycline-induced cardiomyopathy (AIC). First, we discuss inflammation associated with anthracyclines at a cellular level. Next, we discuss the clinical implications of these inflammatory mechanisms for early detection and cardioprotective strategies in patients undergoing anthracycline treatment.
View Article and Find Full Text PDFAdd-on multidrug treatment based on quadruple therapy successfully treated worsening heart failure caused by anthracycline-induced cardiomyopathy in a survivor of cancer as a young adult: a case report.
BMC Cardiovasc Disord
September 2024
Department of Cardiology, Niigata City General Hospital, 463-7, Shumoku, Chuo-ku, Niigata, 950-1197, Japan.
Article Synopsis
- * A case study featured a cancer survivor who experienced heart failure 20 years after treatment, and showed notable improvement when a combination of heart medications, including vericiguat, were introduced.
- * The results suggest that this multidrug approach, including the additions of vericiguat and ivabradine, could effectively manage worsening heart failure in young cancer survivors suffering from severe
Cardio-Oncology's Modern Approaches to Prevent Doxorubicin-Induced Cardiotoxicity: A Systematic Review.
Cureus
August 2024
Internal Medicine, Mayo Clinic, Rochester, USA.
Advances in the field of oncology have led to the advent of doxorubicin (DOX), an anthracycline chemotherapeutic agent, through which cancer survival rates have remarkably improved. There has, however, been a rise in adverse effects from the use of DOX, most notably cardiotoxicity. DOX-induced cardiotoxicity is thought to arise through the generation of reactive oxygen species (ROS), causing mitochondrial dysfunction in the cardiomyocytes.
View Article and Find Full Text PDFArticle Synopsis
- - A woman in her 20s was diagnosed with bulky stage II classic Hodgkin's lymphoma after experiencing symptoms like shortness of breath and cough for eight weeks, leading to the start of a chemotherapy regimen called ABVD.
- - During her treatment, she experienced severe hypertension and tonic-clonic seizures, which were diagnosed as posterior reversible encephalopathy syndrome (PRES), but this improved after stopping chemotherapy and managing her blood pressure.
- - The patient later developed anthracycline-induced cardiomyopathy, prompting a change in her chemotherapy to gemcitabine BVD, but she ultimately recovered fully and completed her treatment, achieving a complete metabolic response to the tumor.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!